Cargando…
Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study
OBJECTIVE: To assess the immunogenicity of pneumococcal 13-valent conjugate vaccination (PCV-13) in patients with rheumatoid arthritis receiving upadacitinib and background methotrexate (MTX). METHODS: Eligible patients from the phase 2 open-label extension trial BALANCE-EXTEND (NCT02049138) receivi...
Autores principales: | Winthrop, Kevin, Vargas, Juan Ignacio, Drescher, Edit, Garcia, Conrado, Friedman, Alan, Hendrickson, Barbara, Li, Yihan, Klaff, Justin, Kivitz, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900062/ https://www.ncbi.nlm.nih.gov/pubmed/35246470 http://dx.doi.org/10.1136/rmdopen-2021-002110 |
Ejemplares similares
-
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study
por: Kivitz, Alan, et al.
Publicado: (2023) -
Pneumococcal vaccination in autoimmune rheumatic diseases
por: Rákóczi, Éva, et al.
Publicado: (2017) -
Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019) -
Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: van Deursen, Anna M.M., et al.
Publicado: (2012) -
Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
por: Gourzoulidis, George, et al.
Publicado: (2023)